ライフサイエンスコーパス: converting enzyme

1 oglobulin, antithrombin III, and angiotensin-converting enzyme.

2 runcated form by tumor necrosis factor alpha-converting enzyme.

3 udes the antihypertensive target angiotensin converting enzyme.

4 e and has a putative action as an endothelin-converting enzyme.

5 he activity of the metalloprotease TNF-alpha-converting enzyme.

6 otons in even the most challenging of energy-converting enzymes.

7 Here, we have identified neural endothelin-converting enzyme 1 (ECE-1) as a key regulator of ET-1-i

8 "CAAX motif." We previously showed that RAS converting enzyme 1 (RCE1)-mediated processing of isopre

9 on, indicating the presence of an endothelin-converting enzyme 1/endothelin 1-SphK positive feedback

10 Endothelin-converting enzyme-1 (ECE-1) is the enzyme predominantly

11 Endothelin-converting enzyme-1 (Ece-1), a crucial component of the

12 n of SphK leads to suppression of endothelin-converting enzyme-1 expression, indicating the presence

13 hia (11%, p = 0.25) and elevated angiotensin-converting enzyme (18%, p = 0.30) were exclusive to SCS.

14 Angiotensin-converting enzyme 2 (ACE2) and its product, angiotensin

15 anism for these disorders; angiotensin (Ang)-converting enzyme 2 (ACE2) negatively regulates RAS by m

16 owed that directed expression of angiotensin-converting enzyme 2 (ACE2) on cells previously resistant

17 With the discovery of the angiotensin-converting enzyme 2 (ACE2), a protective axis of RAS nam

18 me receptor for host cell entry, angiotensin-converting enzyme 2 (ACE2), but it is largely unclear wh

19 etween the RBD and its receptor, angiotensin-converting enzyme 2 (ACE2), to assess their cross-neutra

20 in bronchoalveolar lavage fluid angiotensin-converting enzyme 2 activity were found.

21 The conversion is catalyzed by angiotensin-converting enzyme 2 and other enzymes that selectively c

22 n fetal growth restriction in an angiotensin-converting enzyme 2 knockout mouse model characterized b

23 nced BP, decreased expression of angiotensin converting enzyme 2, and increased expression of the Na(

24 approximately 50% homology with angiotensin converting enzyme 2, but without a catalytic domain.

25 giotensin-converting enzyme, and angiotensin-converting enzyme 2.

26 3, agonists of components of the angiotensin-converting enzyme 2/angiotensin(1-7)/Mas receptor axis a

27 In this paper, we report that angiotensin-converting enzyme-2 (ACE2) protected against severe lung

28 Angiotensin-converting-enzyme-2 (ACE2) has been described as a cruci

29 ins were identified as porcine angiotensin-I-converting enzyme (ACE I) and aminopeptidase N (AP-N).

30 extract's capacity to inhibit angiotensin I-converting enzyme (ACE) activity.

31 1h (STP-C1) had the most potent angiotensin converting enzyme (ACE) and dipeptidyl peptidase IV (DPP

32 ii) evaluate the inhibition of angiotensin I-converting enzyme (ACE) by the obtained hydrolysates.

33 Angiotensin-converting enzyme (ACE) can degrade Abeta(1-42), and ACE

34 Somatic angiotensin-converting enzyme (ACE) contains two active sites, the C

35 Angiotensin I-converting enzyme (ACE) hydrolyzes numerous peptides and

36 kidney is an important source of angiotensin-converting enzyme (ACE) in many species, including human

37 diographic screening followed by angiotensin-converting enzyme (ACE) inhibitor and beta-blocker thera

38 To assess the effect of early angiotensin-converting enzyme (ACE) inhibitor therapy in patients wi

39 Adult mice were treated with an angiotensin converting enzyme (ACE) inhibitor, captopril, to evaluat

40 o decrease time-to-resolution of angiotensin-converting enzyme (ACE) inhibitor-associated angioedema

41 with whites when treated with an angiotensin-converting enzyme (ACE) inhibitor-based regimen, but thi

42 heart failure (CHF) with use of angiotensin-converting enzyme (ACE) inhibitor.

43 ative proportion of allergies to angiotensin-converting enzyme (ACE) inhibitors and HMG CoA reductase

44 beta-Blockers and angiotensin-converting enzyme (ACE) inhibitors are widely used cardi

45 benefit from treatments such as angiotensin-converting enzyme (ACE) inhibitors for left ventricular

46 ease) when used as an adjunct to angiotensin-converting enzyme (ACE) inhibitors or angiotensin recept

47 pite optimum treatment including angiotensin-converting enzyme (ACE) inhibitors or angiotensin recept

48 4 inclusive, using terms such as angiotensin-converting enzyme (ACE) inhibitors, adrenaline, allergic

49 that is, renin inhibitors, angiotensin (Ang)-converting enzyme (ACE) inhibitors, Ang II type 1 recept

50 Interventions of interest were angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor

51 duced ejection fraction, such as angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor

52 f them were found identical to angiotensin I-converting enzyme (ACE) inhibitors, antioxidant, antimic

53 Angiotensin-converting enzyme (ACE) inhibitors/angiotensin II recept

54 ides with dual antioxidant and angiotensin I converting enzyme (ACE) inhibitory activities released f

55 peptides with alpha-amylase and angiotensin converting enzyme (ACE) inhibitory activities were succe

56 The angiotensin I-converting enzyme (ACE) inhibitory activity and structur

57 The angiotensin I-converting enzyme (ACE) inhibitory activity of protein h

58 but at the same time increased angiotensin I-converting enzyme (ACE) inhibitory activity, and in vitr

59 etoses showed moderate to weak angiotensin I converting enzyme (ACE) inhibitory activity.

60 Angiotensin I converting enzyme (ACE) inhibitory and antioxidant pepti

61 lted in the generation of potent angiotensin converting enzyme (ACE) inhibitory hydrolysates.

62 Angiotensin I-converting enzyme (ACE) inhibitory peptides derived from

63 Antioxidant and angiotensin converting enzyme (ACE) inhibitory peptides were extract

64 nt amino acid compositions and angiotensin I-converting enzyme (ACE) inhibitory potentials.

65 Angiotensin-I converting enzyme (ACE) is a zinc dipeptidylcarboxypepti

66 Angiotensin-I converting enzyme (ACE) is a zinc metalloprotease consis

67 1Inh, C4, spontaneous amidase, angiotensin-I-converting enzyme (ACE), aminopeptidase P (APP), and car

68 in (REN), angiotensinogen (AGT), angiotensin-converting enzyme (ACE), angiotensin II type 1 receptor

69 a peptidase related to mammalian angiotensin-converting enzyme (ACE), are insecticidal to larvae of t

70 1); we assayed the activity of angiotensin I converting enzyme (ACE), which catalyses the production

71 Angiotensin-converting enzyme (ACE)-2 is the primary enzyme of the v

72 investigation was to compare the angiotensin converting enzyme (ACE)-inhibitory activity of the hydro

73 hydrolysed sample showed high angiotensin I converting enzyme (ACE)-inhibitory and antioxidant activ

74 are efficient inhibitors of the angiotensin-converting enzyme (ACE).

75 Angiotensin-I-converting enzyme (ACE-I) plays a key role in control of

76 Genes encoding angiotensin-converting enzymes (Ace and Ace2) are essential for hear

77 and alpha-amylase, inhibition of angiotensin-converting enzymes (ACE), and direct vaso-relaxant effec

78 in-receptor blocker (ARB) and an angiotensin-converting-enzyme (ACE) inhibitor (odds ratio 0.62, 95%

79 efficacy of monotherapy with an angiotensin-converting-enzyme (ACE) inhibitor or angiotensin II-rece

80 oedema induced by treatment with angiotensin-converting-enzyme (ACE) inhibitors accounts for one thir

81 min excretion might benefit from angiotensin-converting-enzyme (ACE) inhibitors and statins, drugs th

82 ents with chronic heart failure, angiotensin-converting-enzyme (ACE) inhibitors reduce mortality and

83 hydrolysates the antioxidant and angiotensin-converting-enzyme (ACE) inhibitory activities were measu

84 nd alpha-glucosidase inhibition, angiotensin-converting-enzyme (ACE)-inhibition, antioxidant and prot

85 patients known to be tolerant to angiotensin-converting-enzyme (ACE)-inhibitors were randomly assigne

86 tic biomarkers (eg, lysozyme and angiotensin-converting enzyme [ACE]) are lacking in high sensitivity

87 Angiotensin-I-converting enzyme activities were 58 (44-76) and 49 (35-

88 These MPs exhibited angiotensin-converting enzyme activity and upregulated AT1 receptors

89 Changes in basal tumor necrosis factor-alpha-converting enzyme activity at day 0 for sepsis patients

90 nges in monocyte tumor necrosis factor-alpha-converting enzyme activity could be induced in healthy v

91 In addition, membrane-bound angiotensin-converting enzyme activity decreased.

92 and mechanical ventilated rats, angiotensin-converting enzyme activity in bronchoalveolar lavage flu

93 This enhanced TNF-alpha-converting enzyme activity significantly increases the r

94 levels of basal tumor necrosis factor-alpha-converting enzyme activity that were refractory to lipop

95 of p75(NTR) by the metalloprotease TNFalpha-converting enzyme and gamma-secretase is necessary for p

96 Increased serum levels of angiotensin converting enzyme and lysozyme are considered as inflamm

97 ificance of differences in serum angiotensin converting enzyme and lysozyme levels of patients with o

98 The serum levels of angiotensin converting enzyme and lysozyme were analyzed by enzyme-l

99 to an enhanced activity of ADAM17 (TNF-alpha converting enzyme) and matrix metalloprotease 14 caused

100 monary renin-angiotensin system, angiotensin-converting enzyme, and angiotensin-converting enzyme 2.

101 , monocyte basal tumor necrosis factor-alpha-converting enzyme, and its induction by lipopolysacchari

102 ion of angiotensin, isolation of angiotensin-converting enzyme, and synthesis of its inhibitors and o

103 relevant in the PFC, where D-serine and its converting enzyme are highly expressed.

104 henYiQi Pills using thrombin and angiotensin converting enzyme as "quality biomarkers".

105 Inhibition of angiotensin-converting enzyme before sepsis worsened the hypotension

106 of the sheddase-tumor necrosis factor-alpha-converting enzyme by Abeta.

107 Monocyte tumor necrosis factor-alpha-converting enzyme catalytic activity appeared altered by

108 chymase-dependent rather than an angiotensin converting enzyme-dependent mechanism.

109 that caspase-8 can act as a direct IL-1beta-converting enzyme during NLRP3 inflammasome activation.

110 Members of the endothelin-converting enzyme (ECE) family are considered good candi

111 ctor production, tumor necrosis factor-alpha-converting enzyme expression and catalytic activity, tum

112 m signaling pathways that induce angiotensin-converting enzyme expression and endothelial dysfunction

113 nd 20-HETE-mediated increases in angiotensin-converting enzyme expression, endothelial dysfunction, s

114 Chest radiography and serum angiotensin-converting enzyme findings were normal.

115 rstanding of how tumor necrosis factor-alpha-converting enzyme function is altered during sepsis will

116 g to introduce the gene encoding the prodrug-converting enzyme herpes simplex virus type 1 thymidine

117 Furthermore, the incorporation of pro-drug converting enzyme, herpes simplex virus thymidine kinase

118 ptidyl peptidase-IV (DPP-IV) and angiotensin converting enzyme I (ACE) inhibition, glucose uptake sti

119 The angiotensin-converting enzyme I (rather than D) allele was significa

120 , also known as interleukin-1beta (IL-1beta)-converting enzyme (ICE), regulates antimicrobial host de

121 ologs of the SARS receptor human angiotensin converting enzyme II (ACE2), replicate efficiently in pr

122 presence of angiotensinogen and angiotensin-converting enzyme in many tissues, renin release in imme

123 nd upregulated AT1 receptors and angiotensin-converting enzyme in P1 ECs.

124 s indicate increased shedding of angiotensin-converting enzyme in the alveolar compartment, thereby s

125 ls correlated with the activity of vitamin A-converting enzymes in mesenteric lymph node dendritic ce

126 tor receptor phosphorylation and angiotensin-converting enzyme induction.

127 Finally, angiotensin-converting enzyme inhibition (captopril) normalized bloo

128 angiotensin receptor blockade or angiotensin-converting enzyme inhibition in DNP.

129 f local AngII production through angiotensin-converting enzyme inhibition prevented glucose-mediated

130 apy (RR 0.63; 95% CI 0.43-0.92), angiotensin-converting enzyme inhibition vs placebo (RR 0.60; 95% CI

131 ctions, including antimicrobial, angiotensin-converting enzyme inhibition, antioxidant, opioid, and i

132 rt failure more effectively than angiotensin-converting enzyme inhibition.

133 al albuminuria during fixed dose angiotensin-converting enzyme inhibition.

134 There is no consensus whether angiotensin-converting enzyme inhibitor (ACEI) and angiotensin recep

135 o assess the association between angiotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor

136 s losartan and valsartan and the angiotensin-converting enzyme inhibitor captopril on wound healing i

137 noparticles for the detection of angiotensin-converting enzyme inhibitor drug, captopril, is presente

138 r LCZ696 (400 mg daily) with the angiotensin-converting enzyme inhibitor enalapril (20 mg daily) in 8

139 ction (HFrEF), compared with the angiotensin-converting enzyme inhibitor enalapril, and improves peri

140 d blood pressure lowering in the angiotensin-converting enzyme inhibitor group (p < 0.001).

141 was significantly higher in the angiotensin-converting enzyme inhibitor group than in the other grou

142 n was significantly lower in the angiotensin-converting enzyme inhibitor group than in the other grou

143 sin inhibitor was superior to an angiotensin-converting enzyme inhibitor in reducing mortality in pat

144 The angiotensin converting enzyme inhibitor lisinopril and mineralocorti

145 -aldosterone pathway, such as an angiotensin-converting enzyme inhibitor or an angiotensin receptor b

146 and 18.2% of patients not on an angiotensin-converting enzyme inhibitor or angiotensin II receptor b

147 and overt nephropathy receiving angiotensin converting enzyme inhibitor or angiotensin receptor bloc

148 e baseline renal function, lower angiotensin-converting enzyme inhibitor or angiotensin receptor bloc

149 ption of beta-blocker and either angiotensin-converting enzyme inhibitor or angiotensin receptor bloc

150 antihypertensive therapy with an angiotensin-converting enzyme inhibitor or angiotensin receptor bloc

151 NYHA) classification, and use of angiotensin-converting enzyme inhibitor or angiotensin receptor bloc

152 enal disease classification, and angiotensin converting enzyme inhibitor or angiotensin receptor bloc

153 systolic, <90 mm Hg diastolic), angiotensin-converting enzyme inhibitor or angiotensin receptor bloc

154 5, or 10 years, with subsequent angiotensin-converting enzyme inhibitor or beta-blocker treatment fo

155 not in MFS mice treated with an angiotensin-converting enzyme inhibitor or lacking angiotensinogen.

156 It is an angiotensin-converting enzyme inhibitor that operates via chelating

157 f avascular necrosis, and use of angiotensin-converting enzyme inhibitor therapy for microalbuminuria

158 ntify patients with COPD in whom angiotensin-converting enzyme inhibitor therapy improves renal and l

159 s of sacubitril-valsartan versus angiotensin-converting enzyme inhibitor therapy in patients with chr

160 ignificant clinical benefit from angiotensin-converting enzyme inhibitor therapy regardless of renal

161 ve greater clinical benefit from angiotensin-converting enzyme inhibitor therapy.

162 tor-Neprilysin Inhibitor With an Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Globa

163 eleterious hemodynamic effect of angiotensin-converting enzyme inhibitor treatment in mice.

164 ngs support the possibility that angiotensin-converting enzyme inhibitor treatment might limit PEC ac

165 wever, retrospective analysis of angiotensin-converting enzyme inhibitor trials and prospective compa

166 angiotensin II receptor blocker/angiotensin-converting enzyme inhibitor use were associated with red

167 RAAS inhibition by enalapril (angiotensin-converting enzyme inhibitor) or losartan (angiotensin-re

168 neprilysin inhibitor) with ACEI (angiotensin-converting enzyme inhibitor) to Determine Impact on Glob

169 were taking azathioprine and an angiotensin-converting enzyme inhibitor, 171 (12.9%) were taking a s

170 nitiating drug treatment with an angiotensin-converting enzyme inhibitor, angiotensin receptor blocke

171 ications include a beta-blocker, angiotensin-converting enzyme inhibitor, oral antidiabetic agent, ca

172 of sacubitril/valsartan, over an angiotensin-converting enzyme inhibitor, was consistent regardless o

173 editary angioedema type III, and angiotensin converting enzyme inhibitor-induced angioedema.

174 kade during hemorrhagic shock in angiotensin-converting enzyme inhibitor-treated mice.

175 benefit could be of interest in angiotensin-converting enzyme inhibitor-treated patients during both

176 pretreatment with enalapril, an angiotensin converting enzyme inhibitor.

177 ntion, in-hospital and discharge angiotensin-converting enzyme inhibitor/angiotensin II receptor bloc

178 e characteristics (shock, use of angiotensin-converting enzyme inhibitor/angiotensin II receptor bloc

179 ion of statin, beta-blocker, and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker

180 drug, statin, beta-blocker, and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker

181 uretic peptide, pkVO2, NYHA, and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker

182 subset received at least 1 GDMT (angiotensin-converting enzyme inhibitor/angiotensin receptor blocker

183 o 110/75 mm Hg) and to either an angiotensin-converting-enzyme inhibitor (lisinopril) plus an angiote

184 Neprilysin Inhibitor] with ACEI [Angiotensin-Converting-Enzyme Inhibitor] to Determine Impact on Glob

185 Neprilysin Inhibitor] with ACEI [Angiotensin-Converting-Enzyme Inhibitor] to Determine Impact on Glob

186 Neprilysin Inhibitor] With ACEI [Angiotensin-Converting-Enzyme Inhibitor] to Determine Impact on Glob

187 proteinase/TACE (tumor necrosis factor-alpha-converting enzyme) inhibitor GM6001 was ineffective.

188 occurrence of the casein-derived angiotensin converting enzyme-inhibitor (ACE-I) peptides VPP, IPP, R

189 rtan was more effective than the angiotensin-converting enzyme inhibitorenalapril in patients with he

190 The association between angiotensin-converting enzyme inhibitors (ACEI) and angiotensin rece

191 Angiotensin-converting enzyme inhibitors (ACEi) for renin-angiotensi

192 ian-directed therapy with either angiotensin-converting enzyme inhibitors (ACEI) or angiotensin recep

193 Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin recep

194 Although statins, angiotensin-converting enzyme inhibitors (ACEI) or angiotensin recep

195 ced ejection fraction, including angiotensin-converting enzyme inhibitors (ACEI), angiotensin recepto

196 ed potassium excretion caused by angiotensin-converting enzyme inhibitors (ACEis) and angiotensin rec

197 Angiotensin-converting enzyme inhibitors (ACEIs) may retard the deve

198 Angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin rece

199 l studies have shown that use of angiotensin-converting enzyme inhibitors (ACEIs) potentially decreas

200 lcium channel blockers (CCBs) or angiotensin-converting enzyme inhibitors (ACEis), respectively.

201 ased risk was found for users of angiotensin-converting enzyme inhibitors (adjusted OR 1 .

202 1 receptor antagonists (n=6) or angiotensin-converting enzyme inhibitors (n=6) exhibited no signific

203 ) immediately before anesthesia (angiotensin-converting enzyme inhibitors + icatibant), and 5) shocke

204 (antiplatelet therapy, statins, angiotensin-converting enzyme inhibitors [ACEIs] or angiotensin rece

205 which the medication was taken (angiotensin-converting enzyme inhibitors [ACEIs], angiotensin recept

206 ck, 4) shocked mice treated with angiotensin-converting enzyme inhibitors and a single bolus of icati

207 each of 6 drug classes: statins, angiotensin-converting enzyme inhibitors and angiotensin II receptor

208 Uptitration of angiotensin-converting enzyme inhibitors and beta blockers was perfo

209 Angiotensin-converting enzyme inhibitors and beta-blockers are recom

210 We hypothesized that angiotensin-converting enzyme inhibitors and beta-blockers could pre

211 Current standard therapy with angiotensin-converting enzyme inhibitors and/or angiotensin receptor

212 Angiotensin-converting enzyme inhibitors are associated with deleter

213 use the pharmacologic effects of angiotensin-converting enzyme inhibitors are partly mediated by incr

214 Angiotensin-converting enzyme inhibitors can delay the progression o

215 ude calcium channel blockers and angiotensin-converting enzyme inhibitors for cardiovascular protecti

216 rin, statins, beta-blockers, and angiotensin-converting enzyme inhibitors given to patients after myo

217 and patients with intolerance to angiotensin-converting enzyme inhibitors or angiotensin II receptor

218 eceptor inhibitors, statins, and angiotensin-converting enzyme inhibitors or angiotensin receptor blo

219 tions, and contraindications for angiotensin-converting enzyme inhibitors or angiotensin receptor blo

220 cations (statins, beta-blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blo

221 dosterone system with the use of angiotensin-converting enzyme inhibitors or angiotensin receptor blo

222 e diagnosis of HF, initiation of angiotensin-converting enzyme inhibitors or angiotensin receptor blo

223 at discharge were not receiving angiotensin-converting enzyme inhibitors or angiotensin receptor blo

224 receiving beta-blockers and 81% angiotensin-converting enzyme inhibitors or angiotensin receptor blo

225 ot among those only treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blo

226 beta-blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blo

227 ertensive medications other than angiotensin-converting enzyme inhibitors or angiotensin receptor blo

228 ing insulin, and 84% were taking angiotensin-converting enzyme inhibitors or angiotensin receptor blo

229 roteinuria >1 g/d, maintained on angiotensin-converting enzyme inhibitors or angiotensin receptor blo

230 cribing appropriate medications (angiotensin-converting enzyme inhibitors or angiotensin-receptor blo

231 All patients were treated with angiotensin-converting enzyme inhibitors or angiotensin-receptor blo

232 stem (RAS) blockade therapy with angiotensin-converting enzyme inhibitors or angiotensin-receptor blo

233 cribing appropriate medications (angiotensin-converting enzyme inhibitors or angiotensin-receptor blo

234 and less likely to be prescribed angiotensin-converting enzyme inhibitors or beta-blockers.

235 ted, BALB/c mice pretreated with angiotensin-converting enzyme inhibitors potentiated IFN-gamma produ

236 that angiotensin II (Ang II) and angiotensin converting enzyme inhibitors regulated blood EPO levels.

237 ced by trials that have compared angiotensin-converting enzyme inhibitors with drugs that inhibit bot

238 reated with ramipril for 7 days (angiotensin-converting enzyme inhibitors) before hemorrhagic shock,

239 ngiotensin II receptor blockers, angiotensin-converting enzyme inhibitors) can modify the host respon

240 %) of patients were treated with angiotensin-converting enzyme inhibitors, 34% (95% CI: 28%-41%) with

241 beta-adrenergic blocking agents, angiotensin-converting enzyme inhibitors, and angiotensin receptor b

242 dicines (aspirin, beta blockers, angiotensin-converting enzyme inhibitors, and statins) in pharmacies

243 Angiotensin-converting enzyme inhibitors, angiotensin receptor block

244 500-5000 mg/g) and taking stable angiotensin-converting enzyme inhibitors, angiotensin receptor block

245 on permitted background drugs of angiotensin-converting enzyme inhibitors, angiotensin-receptor block

246 No class of medications (i.e., angiotensin-converting enzyme inhibitors, angiotensin-receptor block

247 medication classes examined were angiotensin-converting enzyme inhibitors, angiotensin-receptor block

248 ubsequently filled prescriptions angiotensin-converting enzyme inhibitors, beta-blockers, and statins

249 ed antiplatelet agents, statins, angiotensin-converting enzyme inhibitors, blood pressure control, li

250 of days covered for statins and angiotensin-converting enzyme inhibitors, patients were stratified a

251 nd 54% were on beta-blockers and angiotensin-converting enzyme inhibitors, respectively.

252 hormonal replacement therapy, or angiotensin-converting enzyme inhibitors.

253 often on diuretics, digoxin, and angiotensin converting enzyme inhibitors.

254 ion of ejection fraction, use of angiotensin-converting enzyme inhibitors/angiotensin receptor antago

255 74-1.01) in patients on statins, angiotensin-converting enzyme inhibitors/angiotensin receptor blocke

256 ient adherence to beta-blockers, angiotensin-converting enzyme inhibitors/angiotensin receptor blocke

257 a combination of beta-blockers, angiotensin-converting enzyme inhibitors/angiotensin receptor blocke

258 ividuals, 55%, 76%, and 61% used angiotensin-converting enzyme inhibitors/angiotensin receptor blocke

259 ut women were less likely to use angiotensin-converting enzyme inhibitors/angiotensin receptor blocke

260 ts of treatment with statins and angiotensin-converting enzyme inhibitors/angiotensin receptor blocke

261 of the patients were on statins, angiotensin-converting enzyme inhibitors/angiotensin receptor blocke

262 tment at discharge with statins, angiotensin-converting enzyme inhibitors/angiotensin receptor blocke

263 n rural; P=0.1) and reversed for angiotensin-converting enzyme inhibitors/angiotensin receptor blocke

264 giotensin receptor blockers, and angiotensin-converting enzyme inhibitors; prophylactic surgery for a

265 te significantly associated with angiotensin-converting-enzyme inhibitors in our metabolome-wide asso

266 duction of medications including angiotensin-converting-enzyme inhibitors, angiotensin-receptor block

267 ABA) content (6.8-10.6 mg/g) and angiotensin converting enzyme inhibitory (ACEI) activity (>90%).

268 olysis and negatively affected angiotensin I-converting enzyme inhibitory activity of fermented lenti

269 tivity (antioxidant effect and angiotensin I-converting enzyme inhibitory activity), rheological, and

270 tterness and umami, as well as angiotensin-I converting enzyme inhibitory activity.

271 The angiotensin converting enzyme-inhibitory activity was significantly

272 sociated death domain-like interleukin-1beta-converting enzyme-inhibitory protein (vFLIP) increased S

273 Chorismatases are a class of chorismate-converting enzymes involved in the biosynthetic pathways

274 Laboratory results showed high angiotensin converting enzyme level being significantly more likely

275 a significant increase in serum angiotensin converting enzyme level in patients with presumed sarcoi

276 Elevated serum angiotensin converting enzyme levels are significant for patients wi

277 receptor (CHRNG, 6 subjects) and endothelin converting enzyme-like 1 (ECEL1, 4 subjects).

278 In this study, we show that following TNF-converting enzyme-mediated ectodomain shedding of TNF ty

279 3 plus BQ788) or by inhibition of endothelin-converting enzyme (phosphoramidon or SM19712).

280 FAs) induced the expression of the vitamin A-converting enzyme RALDH1 in intestinal epithelial cells

281 hies, neurological disorders, and cancer, PI-converting enzymes represent potential targets for drug-

282 d the attenuated tumor necrosis factor-alpha-converting enzyme response to lipopolysaccharide was ass

283 )CD11b(+) DC subset expressing the vitamin A-converting enzyme retinaldehyde dehydrogenase and specia

284 d sickle cell anaemia, and serum angiotensin-converting enzyme (SACE) measurement to exclude sarcoido

285 Somatic angiotensin-converting enzyme (sACE), a key regulator of blood press

286 Together with the presence of angiotensin-converting enzyme-sheddase ADAM9 (a disintegrin and meta

287 Inhibition of angiotensin-converting enzyme slows progression to kidney failure in

288 mammalian metalloproteases such as TNFalpha converting enzyme (TACE) (Ki = 4.45 +/- 0.48 muM).

289 n And Metalloproteinase 17 (ADAM17)/TNFalpha Converting Enzyme (TACE) is associated with inflammatory

290 sTNF is generated by TNF-alpha converting enzyme (TACE) proteolytic release of the tran

291 and tumour necrosis factor-alpha (TNF-alpha) converting enzyme (TACE) were also assessed.

292 by suppressing the activity of the TNF-alpha-converting enzyme (TACE), arguing that MUC1 is required

293 ding mediated by tumor necrosis factor-alpha-converting enzyme (TACE), enhanced CXCL12-CXCR4-induced

294 xpression of AR and its activator, TNF-alpha converting enzyme (TACE).

295 ytic activity of tumor necrosis factor alpha-converting enzyme (TACE; ADAM17, CD156b), the metallopro

296 o associated with a reduction of angiotensin-converting enzyme type 2 (ACE2) and an increase in a dis

297 the tmTNF cleavage metalloprotease TNF-alpha-converting enzyme via p38 MAP kinase activation and its

298 ddition, the production of angiotensin (Ang)-converting enzyme was upregulated in TGFBR1 deficient ao

299 The activity of angiotensin-converting enzyme, which catalyses production of the vas

300 toward the lung injury-promoting angiotensin-converting enzyme, which may form an explanation for the